title: Biphasic response of the metallothionein promoter to ultraviolet radiation in human melanoma cells.
abstract: Because metallothionein (MT) is elevated and may be protective in UV-irradiated skin, we have studied the effects of UV and other agents on MT transcription using the sheep MT 1A promoter, linked to the beta-galactosidase gene and stably transfected into human cell lines. beta-galactosidase reporter activity was inducible by adding Zn2+ ions to the medium (100 microM for 2-4 h). Two differentiating agents, butyric acid and azelaic bishydroxamic acid (ABHA), significantly increased the response to Zn2+ in a melanoma cell line (MM96L-gal). UVB (280-315 nm) had two distinct, time-dependent effects. During the first 4 h after irradiation, high doses of UVB inhibited induction by Zn2+, an effect that was made more acute by simultaneous exposure to the differentiating agents. These changes in reporter activity were not due to alterations in Zn2+ transport into the cell. The UVB-depressed MT response subsequently recovered and by 24 h was double the control, yet remained sensitive to ABHA. Reporter activity in transfected HeLa cells differed from that in MM96L, being depressed 4 and 24 h after UVB and insensitive to ABHA at both times. Galactosidase reporter activity driven by non-MT promoters was not affected by these treatments. Dependence of MT transcriptional activity on UV-related DNA damage could be inferred because equitoxic UVC (254 nm) affected the response to Zn2+ in a similar fashion, whereas UVA, cisplatin and a methylating agent had no effect. The MT response was partly dependent on the PKC signal transduction pathway because it was inhibited by phorbol ester in HeLa, and by bisindolyl maleimide in HeLa and MM96L. The biphasic MT transcriptional response may model a signal transduction pathway that gives an early, depressed response to acute UV damage, with exacerbation by concurrent differentiation stimuli, but switches to a positive, cell-specific and potentially protective response at later times.
authors.affiliation: Queensland Cancer Fund Laboratories, Queensland Institute of Medical Research, Herston, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Hansen
authors.forename: E
authors.initials: E
authors.lastname: Ablett
authors.forename: A
authors.initials: A
authors.lastname: Green
authors.forename: R A
authors.initials: RA
authors.lastname: Sturm
authors.forename: I S
authors.initials: IS
authors.lastname: Dunn
authors.forename: D P
authors.initials: DP
authors.lastname: Fairlie
authors.forename: M L
authors.initials: ML
authors.lastname: West
authors.forename: P G
authors.initials: PG
authors.lastname: Parsons
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D006367:HeLa Cells; D006801:Humans; D008545:Melanoma / Q000473:pathology*; D008668:Metallothionein / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000528:radiation effects*; D012756:Sheep; D012878:Skin Neoplasms / Q000473:pathology; D014407:Tumor Cells, Cultured; D014466:Ultraviolet Rays
chemical_list: D008668:Metallothionein